Directed engagement of activating Fc receptors
The present invention features engineered proteins that include a first polypeptide that specifically binds a first target (e.g., a cellular target, such as a cell-surface antigen) and a second polypeptide that selectively binds an activating FcR.
1. An engineered protein comprising a first polypeptide that specifically binds a cellular target and a second polypeptide that specifically binds an activating Fc gamma receptor IIA or IIIA, wherein the second polypeptide comprises a variant fibronectin 3 (Fn3) domain amino acid sequence that is at least 70% identical to SEQ ID NO:1, and wherein the variant Fn3 domain comprises a BC domain, a DE domain, and a FG domain, and wherein at least six of the eight amino acids in the BC domain are substituted or deleted, relative to SEQ ID NO:1.
2. The engineered protein of claim 1 , wherein the second polypeptide has an affinity for the activating Fc receptor of about 100 nM.
3. The engineered protein of claim 1 , wherein the first polypeptide comprises an immunoglobulin or an antigen-binding fragment thereof.
4. The engineered protein of claim 3 , wherein the immunoglobulin is an immunoglobulin of the G class (IgG).
5. The engineered protein of claim 4 , wherein the IgG is an IgG1.
6. The engineered protein of claim 1 , wherein the first polypeptide is a human polypeptide.
7. The engineered protein of claim 3 , wherein the immunoglobulin is a human or humanized immunoglobulin.
8. The engineered protein of claim 1 , wherein the cellular target is a cancer antigen.
9. The engineered protein of claim 3 , wherein the immunoglobulin is abciximab, adalimumab, alemtuzumab, basiliximab, bevacizumab, certuximab, certolizumab pegol, daclizumab, eculizumab, efalizumab, gemtuzumab, ibrutumomab tiuxetan, Infliximab, muromonab-CD3, natalizumab, omalizumab, palivizumab, panitumumab, ranibizumab, rituximab, tositumomab, or trastuzumab.
10. The engineered protein of claim 9 , wherein the second polypeptide is covalently bound to the carboxy terminus of the immunoglobulin or the antigen binding fragment thereof.
11. A nucleic acid comprising a sequence encoding the engineered protein of claim 1 .
12. An expression vector comprising the nucleic acid of claim 11 and a regulatory sequence.
13. An isolated host cell comprising the expression vector of claim 12 .
14. A pharmaceutical composition comprising the engineered protein of claim 1 .
15. A method of treating a patient diagnosed as having cancer, the method comprising administering to the patient the engineered protein of claim 1 , wherein the first polypeptide is an immunoglobulin or antigen-binding fragment thereof that specifically binds a cell surface cancer antigen expressed in the patient, wherein the immunoglobulin or antigen-binding fragment thereof is conjugated to a cytotoxic agent.
16. The engineered protein of claim 1 , wherein at least three of the five amino acid residues of the DE loop are substituted or deleted and at least eight of the ten amino acid residues of the FG loop are substituted or deleted, relative to SEQ ID NO:1.
17. The engineered protein of claim 1 , wherein the BC, DE, and FG domains of the variant Fn3 domain comprise the amino acid sequences:
a) SEQ ID NO: 39, SEQ ID NO: 46, and SEQ ID NO: 50, respectively;
b) amino acids 23-27 of SEQ ID NO: 4, amino acids 51-55 of SEQ ID NO: 4, and amino acids 76-81 of SEQ ID NO: 4, respectively;
c) conservative amino acid substitutions to SEQ ID NO: 39, SEQ ID NO: 46, and SEQ ID NO: 50, respectively; or
d) conservative amino acid substitutions to amino acids 23-27 of SEQ ID NO: 4, amino acids 51-55 of SEQ ID NO: 4, and amino acids 76-81 of SEQ ID NO: 4, respectively.
18. A protein comprising a variant fibronectin 3 (Fn3) domain amino acid sequence that is at least 70% identical to SEQ ID NO:1 and specifically binds an activating Fc gamma receptor IIA or IIIA, wherein the variant Fn3 domain comprises a BC domain, a DE domain, and a FG domain comprising the amino acid sequences:
a) SEQ ID NO: 39, SEQ ID NO: 46, and SEQ ID NO: 50, respectively;
b) amino acids 23-27 of SEQ ID NO: 4, amino acids 51-55 of SEQ ID NO: 4, and amino acids 76-81 of SEQ ID NO: 4, respectively;
c) conservative amino acid substitutions to SEQ ID NO: 39, SEQ ID NO: 46, and SEQ ID NO: 50, respectively; or
d) conservative amino acid substitutions to amino acids 23-27 of SEQ ID NO: 4, amino acids 51-55 of SEQ ID NO: 4, and amino acids 76-81 of SEQ ID NO: 4, respectively.
19. A fusion protein comprising the protein of claim 18 linked to the C-terminus of a heterologous amino acid sequence that specifically binds a cellular target other than activating Fc gamma receptor IIA or IIIA.
20. The fusion protein of claim 19 , wherein the heterologous amino acid sequence comprises the antigen-binding fragment of an antibody.
21. An engineered protein comprising a first polypeptide that specifically binds a cellular target and a second polypeptide that specifically binds an activating Fc gamma receptor IIA or IIIA, wherein the second polypeptide is selected from the group consisting of SEQ ID NOs: 2-35.
22. The engineered protein of claim 21 , wherein the first polypeptide comprises an immunoglobulin or an antigen-binding fragment thereof.
23. The engineered protein of claim 22 wherein the immunoglobulin is a human or humanized immunoglobulin.
24. The engineered protein of claim 22 , wherein the immunoglobulin is abciximab, adalimumab, alemtuzumab, basiliximab, bevacizumab, certuximab, certolizumab pegol, daclizumab, eculizumab, efalizumab, gemtuzumab, ibrutumomab tiuxetan, Infliximab, muromonab-CD3, natalizumab, omalizumab, palivizumab, panitumumab, ranibizumab, rituximab, tositumomab, or trastuzumab.
25. The engineered protein of claim 21 , wherein the second polypeptide is SEQ ID NO: 2.
26. The engineered protein of claim 21 wherein the second polypeptide is SEQ ID NO: 3.
27. The engineered protein of claim 21 wherein the second polypeptide is SEQ ID NO: 4.
28. The engineered protein of claim 21 , wherein the second polypeptide is SEQ ID NO: 5.